Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target Raised to $24.00

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target raised by JPMorgan Chase & Co. from $22.00 to $24.00 in a report published on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other research analysts have also issued research reports about the stock. Leerink Partners began coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 target price for the company. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Zacks Research lowered Amneal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Finally, Weiss Ratings raised Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

Amneal Pharmaceuticals Trading Down 0.5%

NASDAQ:AMRX opened at $20.38 on Thursday. Amneal Pharmaceuticals has a 12 month low of $9.99 and a 12 month high of $21.17. The firm has a market cap of $6.51 billion, a price-to-earnings ratio of 41.59, a P/E/G ratio of 2.39 and a beta of 1.22. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The company’s 50 day moving average is $18.79 and its 200-day moving average is $16.45.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.95 EPS for the current year.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 50,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the sale, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. This trade represents a 19.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jason B. Daly sold 210,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the sale, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 413,016 shares of company stock worth $7,216,567 in the last ninety days. 17.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AMRX. GAMMA Investing LLC grew its position in Amneal Pharmaceuticals by 54.9% during the third quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock worth $32,000 after buying an additional 569 shares in the last quarter. Fortitude Family Office LLC increased its stake in Amneal Pharmaceuticals by 100.9% during the third quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock valued at $32,000 after acquiring an additional 807 shares during the period. Sterling Capital Management LLC raised its holdings in Amneal Pharmaceuticals by 30.3% in the 3rd quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock valued at $71,000 after acquiring an additional 825 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Amneal Pharmaceuticals by 1.9% in the second quarter. Arizona State Retirement System now owns 44,011 shares of the company’s stock valued at $762,000 after purchasing an additional 837 shares in the last quarter. Finally, Yousif Capital Management LLC lifted its holdings in shares of Amneal Pharmaceuticals by 2.9% during the 3rd quarter. Yousif Capital Management LLC now owns 42,839 shares of the company’s stock worth $863,000 after acquiring an additional 1,197 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.